Radiopharmaceuticals are moving from diagnostic imaging into targeted therapy. Radioligand therapies and theranostic pairs, where one molecule is used both to image and to treat, are among the most active areas of oncology development. Bringing them to patients in Greece and the EU means working through medicines law, radiation protection rules, very short-shelf-life logistics and hospital-based access decisions all at once.
A distinct regulatory category
Directive 2001/83/EC treats radiopharmaceuticals as medicinal products, with specific definitions for radionuclide generators, kits and radionuclide precursors. Two points stand out:
- Under Article 7, no marketing authorisation is required for a radiopharmaceutical prepared at the time of use in an approved healthcare establishment, by an authorised person, exclusively from authorised generators, kits or precursors and in line with the manufacturer’s instructions. The generators, kits and precursors themselves need authorisation.
- Manufacturing follows EU GMP, with a dedicated annex on radiopharmaceuticals that addresses radiation safety, aseptic processing and release under time pressure.
Radiation protection runs alongside
Medicines law is only half the picture. The Euratom Basic Safety Standards Directive (2013/59/Euratom) governs medical exposure, licensing of practices and justification of procedures. In Greece, the Greek Atomic Energy Commission (EEAE) oversees radiation protection, so hospitals, nuclear medicine departments and suppliers need the appropriate licences in place before a new therapy can be used. Company launch plans need to allow time for this.
Supply chain realities
Short half-lives change the rules of pharmaceutical logistics:
- shelf lives measured in hours or days rather than years
- production scheduled around each patient and treatment slot
- batch certification and release designed to fit the time available
- dependence on a small number of reactors and isotope producers, an area the EU has flagged as strategic in its SAMIRA action plan on medical applications of ionising radiation.
For a Greek launch, delivery routes from the manufacturing site to treatment centres, and contingency plans for delays, have to be designed early.
The access question
Radioligand therapies are usually given in hospitals, so access depends on more than the price of the medicine:
- Infrastructure: shielded facilities, isolation capacity where required and trained nuclear medicine staff.
- Diagnostic pairing: the companion imaging agent and scan must also be available and funded.
- Budget holders: costs fall across the medicine budget, procedure funding and hospital resources, which affects how a budget impact analysis should be structured.
- Evidence: HTA submissions should reflect the whole care pathway, not only the therapy.
How PQRA helps
PQRA supports radiopharmaceutical developers and distributors with regulatory strategy, GMP and supply chain quality, and Greek market access planning. We help connect the medicines, radiation protection and hospital access workstreams so that a positive opinion turns into patients actually treated.


No responses yet